Juan Lopez-Mattei
Research Subjects
Juan Lopez-Mattei has a total of 441 co-authors. Here are the top co-authors by number of shared publications:
- Cezar Iliescu
University of Texas MD Anderson Cancer Center
28 shared publications Peter Kim
Department of Cardiology, Loma Linda University Medical Center, Loma Linda, CA, United States
25 shared publicationsCezar Iliescu
Heart and Vascular Institute, Lee Health, Fort Myers, FL, USA
21 shared publications- Nicolas L. Palaskas
Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
14 shared publications Nicolas Palaskas
Department of Cardiology, Loma Linda University Medical Center, Loma Linda, CA, United States
14 shared publicationsSaamir Hassan
Department of Cardiology, Loma Linda University Medical Center, Loma Linda, CA, United States
13 shared publications
Latest Publications
- Open Access
- 7 February 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (3) , 102523
Preprocedural and Postprocedural CT Imaging Can Identify Patients at Risk for Complications After LAA Occlusion
- 7 February 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (3) , 102523
Open AccessPreprocedural and Postprocedural CT Imaging Can Identify Patients at Risk for Complications After LAA Occlusion
- Open Access
- 7 October 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (36) , 105612
Radiation Dose Optimization in a Multicenter CCTA Program
- 7 October 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (36) , 105612
Open AccessRadiation Dose Optimization in a Multicenter CCTA Program
- Open Access
- 13 August 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (23) , 104118
Transcatheter Relief for Lipomatous Hypertrophy of an Interatrial Septum Obstructing Superior Vena Cava in an Elderly Patient
- 13 August 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (23) , 104118
Open AccessTranscatheter Relief for Lipomatous Hypertrophy of an Interatrial Septum Obstructing Superior Vena Cava in an Elderly Patient
- 11 January 2025
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 19 (1) , 72-73
Modern CT detector technology and innovations in image reconstruction enhance cardiovascular CT
- 11 January 2025
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 19 (1) , 72-73
Modern CT detector technology and innovations in image reconstruction enhance cardiovascular CT
- Open Access
- 11 November 2024
- Published by Elsevier in JACC: Advances
- Vol. 3 (12) , 101393
Rheumatic Heart Disease Burden
- 11 November 2024
- Published by Elsevier in JACC: Advances
- Vol. 3 (12) , 101393
Open AccessRheumatic Heart Disease Burden
- 4 November 2024
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 17 (11) , 1348-1350
Improving Precision and Refining Risk Prediction of CTRCD With Cardiovascular CT
- 4 November 2024
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 17 (11) , 1348-1350
Improving Precision and Refining Risk Prediction of CTRCD With Cardiovascular CT
- Top Cited PapersOpen Access
- 29 October 2024
- Published by Elsevier in JACC: Cardiooncology
- Vol. 6 (6) , 847-862
Multimodality Imaging in the Diagnostic Work-Up of Patients With Cardiac Masses
- 29 October 2024
- Published by Elsevier in JACC: Cardiooncology
- Vol. 6 (6) , 847-862
Top Cited PapersOpen AccessMultimodality Imaging in the Diagnostic Work-Up of Patients With Cardiac Masses
- Open Access
- 15 October 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (10) , 1372
Pembrolizumab-Associated Cardiotoxicity: A Retrospective Analysis of the FDA Adverse Events Reporting System
Background: Immune checkpoint inhibitors (ICIs) have been successfully used in the previous decade for the treatment of a variety of malignancies. Adverse events (AEs) can cause many symptoms, most notably cardiac. We analyzed the frequency of these adverse events, comparing pembrolizumab and other ICIs. Methods: Using the Food and Drug Administration (FDA) adverse event reporting database (FAERS), we searched for all adverse events of interest reported for every ICI included in this study. After obtaining the data, we conducted a disproportionality analysis using the reporting odds ratio (ROR) and the information component (IC). Results: A total of 6719 ICI-related cardiac adverse events of interest were reported in the database. Serious outcomes were reported in 100% of the cases, with 34.3% of the cases ending fatally. Compared with all other medications in the database, pembrolizumab use was more frequently associated with myocarditis, pericardial disease, heart failure, and atrial fibrillation. No difference was found in cardiotoxicity between different ICIs. Conclusions: Although infrequent, cardiac AEs in pembrolizumab use are associated with serious outcomes and high mortality. Prospective studies are needed to further research the connection between ICI use and cardiotoxicity.
- 15 October 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (10) , 1372
Open AccessPembrolizumab-Associated Cardiotoxicity: A Retrospective Analysis of the FDA Adverse Events Reporting System
Background: Immune checkpoint inhibitors (ICIs) have been successfully used in the previous decade for the treatment of a variety of malignancies. Adverse events (AEs) can cause many symptoms, most notably cardiac. We analyzed the frequency of these adverse events, comparing pembrolizumab and other ICIs. Methods: Using the Food and Drug Administration (FDA) adverse event reporting database (FAERS), we searched for all adverse events of interest reported for every ICI included in this study. After obtaining the data, we conducted a disproportionality analysis using the reporting odds ratio (ROR) and the information component (IC). Results: A total of 6719 ICI-related cardiac adverse events of interest were reported in the database. Serious outcomes were reported in 100% of the cases, with 34.3% of the cases ending fatally. Compared with all other medications in the database, pembrolizumab use was more frequently associated with myocarditis, pericardial disease, heart failure, and atrial fibrillation. No difference was found in cardiotoxicity between different ICIs. Conclusions: Although infrequent, cardiac AEs in pembrolizumab use are associated with serious outcomes and high mortality. Prospective studies are needed to further research the connection between ICI use and cardiotoxicity.
- 3 July 2024
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 39 (4) , 849-856
Are Sodium-Glucose Cotransporter-2 Inhibitors the Cherry on Top of Cardio-Oncology Care?
The increasing aging of the population combined with improvements in cancer detection and care has significantly improved the survival and quality of life of cancer patients. These benefits are hampered by the increase of cardiovascular diseases being heart failure the most frequent manifestation of cardiotoxicity and becoming the major cause of morbidity and mortality among cancer survivor. Current strategies to prevent cardiotoxicity involves different approaches such as optimal management of CV risk factors, use of statins and/or neurohormonal medications, and, in some cases, even the use of chelating agents. As a class, SGLT2-i have revolutionized the therapeutic horizon of HF patients independently of their ejection fraction or glycemic status. There is an abundance of data from translational and observational clinical studies supporting a potential beneficial role of SGLT2-i in mitigating the cardiotoxic effects of cancer patients receiving anthracyclines. These findings underscore the need for more robust clinical trials to investigate the effect on cardiovascular outcomes of the prophylactic SGLT2-i treatment in patients undergoing cancer treatment.
- 3 July 2024
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 39 (4) , 849-856
Are Sodium-Glucose Cotransporter-2 Inhibitors the Cherry on Top of Cardio-Oncology Care?
The increasing aging of the population combined with improvements in cancer detection and care has significantly improved the survival and quality of life of cancer patients. These benefits are hampered by the increase of cardiovascular diseases being heart failure the most frequent manifestation of cardiotoxicity and becoming the major cause of morbidity and mortality among cancer survivor. Current strategies to prevent cardiotoxicity involves different approaches such as optimal management of CV risk factors, use of statins and/or neurohormonal medications, and, in some cases, even the use of chelating agents. As a class, SGLT2-i have revolutionized the therapeutic horizon of HF patients independently of their ejection fraction or glycemic status. There is an abundance of data from translational and observational clinical studies supporting a potential beneficial role of SGLT2-i in mitigating the cardiotoxic effects of cancer patients receiving anthracyclines. These findings underscore the need for more robust clinical trials to investigate the effect on cardiovascular outcomes of the prophylactic SGLT2-i treatment in patients undergoing cancer treatment.